What is the appropriate evaluation and management for a 22‑year‑old woman presenting with gross hematuria?

Evaluation and Management of Gross Hematuria in a 22-Year-Old Woman

A 22-year-old woman with gross hematuria requires urgent urologic evaluation with cystoscopy and upper-tract imaging, even though her age places her in a lower-risk category, because gross hematuria carries a 30–40% malignancy risk regardless of age. 1, 2, 3

Immediate Risk Stratification

This patient is classified as low-to-intermediate risk based on the 2025 AUA/SUFU guidelines, which stratify women under 60 years as low-risk for microscopic hematuria. 1 However, the presence of gross (visible) hematuria automatically elevates concern and mandates complete evaluation regardless of age or other risk factors. 2, 3

Key Risk Factors to Assess

• Smoking history: Women with >10 pack-years move to intermediate risk; >30 pack-years is high-risk for urothelial carcinoma. 1
• Occupational exposures: Benzenes, aromatic amines, or industrial chemicals/dyes significantly increase bladder cancer risk. 1, 3
• Family history: Urologic malignancies or genetic risk factors for bladder/urothelial cancer. 1
• Prior episodes: Any history of previous gross hematuria, even if self-limited, is a high-risk feature. 1, 3
• Irritative voiding symptoms: Urgency, frequency, or dysuria without documented infection suggests possible urothelial malignancy or carcinoma in situ. 2, 3

Mandatory Diagnostic Evaluation

1. Confirm True Hematuria

• Obtain microscopic urinalysis on a properly collected clean-catch specimen showing ≥3 RBCs per high-power field to confirm true hematuria, as dipstick testing has only 65–99% specificity. 2, 3
• Exclude pseudohematuria: Menstrual contamination, myoglobinuria, or hemoglobinuria can cause false-positive dipstick results without actual RBCs on microscopy. 2, 3

2. Upper-Tract Imaging

Multiphasic CT urography is the preferred imaging modality, comprising unenhanced, nephrographic, and excretory phases to evaluate kidneys, collecting systems, ureters, and bladder with 96% sensitivity and 99% specificity for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis. 2, 3, 4

• Alternative imaging (MR urography or renal ultrasound with retrograde pyelography) may be used if CT is contraindicated due to pregnancy, severe renal insufficiency, or contrast allergy. 2, 3
• Renal ultrasound alone is insufficient for comprehensive hematuria evaluation because it cannot reliably assess the ureters, bladder mucosa, or detect small urothelial carcinomas. 3

3. Cystoscopic Examination

Flexible cystoscopy is mandatory for all patients with gross hematuria to directly visualize the bladder mucosa, urethra, and ureteral orifices, as imaging alone cannot exclude bladder cancer. 2, 3

• Flexible cystoscopy is preferred over rigid cystoscopy because it provides equivalent or superior diagnostic accuracy with significantly less patient discomfort. 2, 3
• Bladder cancer accounts for 30–40% of gross hematuria cases, making direct visualization essential even in younger patients. 2, 3, 4

4. Laboratory Evaluation

• Serum creatinine and BUN to assess renal function before contrast administration. 2, 3
• Urine culture (obtained before antibiotics if infection is suspected) to rule out urinary tract infection. 2, 3
• Spot urine protein-to-creatinine ratio to quantify proteinuria; values >0.5 g/g suggest glomerular disease. 2, 3
• Examine urinary sediment for dysmorphic RBCs (>80% suggests glomerular source) and red-cell casts (pathognomonic for glomerulonephritis). 2, 3
• Voided urine cytology is generally reserved for high-risk patients (age >60, smoking >30 pack-years, occupational exposures) and is not recommended as an initial evaluation tool in this age group. 1, 3

Distinguishing Glomerular vs. Urologic Sources

Glomerular Indicators (Prompt Nephrology Referral)

• Tea-colored or cola-colored urine suggests glomerular bleeding. 2, 3
• Dysmorphic RBCs >80% or presence of red-cell casts on microscopy. 2, 3
• Protein-to-creatinine ratio >0.5 g/g (≈500 mg/24h). 2, 3
• Elevated serum creatinine or declining renal function. 2, 3
• Hypertension accompanying hematuria and proteinuria. 2, 3

Even when glomerular features are present, complete urologic evaluation remains necessary because malignancy can coexist with medical renal disease. 2, 3

Urologic Indicators

• Normal-shaped RBCs with minimal or no proteinuria. 2, 3
• Bright red urine suggests lower urinary tract bleeding. 2, 3
• Normal renal function and absence of dysmorphic RBCs or casts. 2, 3

Common Pitfalls to Avoid

• Never dismiss gross hematuria as benign based on age alone—the 30–40% malignancy risk applies to all adults, and delays in diagnosis beyond 9 months are associated with worse cancer-specific survival. 2, 3
• Do not attribute hematuria to menstruation without microscopic confirmation—obtain a catheterized specimen if clean-catch is unreliable. 2, 3
• Do not defer evaluation while awaiting resolution—gross hematuria requires urgent assessment even if self-limited. 2, 3
• Anticoagulant or antiplatelet therapy does not cause hematuria—these medications may unmask underlying pathology, and evaluation must proceed regardless. 2, 3

Follow-Up Protocol

If the initial complete work-up is negative but hematuria persists:

• Repeat urinalysis at 6,12,24, and 36 months with blood pressure monitoring at each visit. 2, 3
• After two consecutive negative annual urinalyses, further testing is unnecessary. 2, 3
• Immediate re-evaluation is warranted if:
  • Recurrent gross hematuria develops 2, 3
  • Significant increase in microscopic hematuria occurs 2, 3
  • New urologic symptoms appear (irritative voiding, flank pain) 2, 3
  • Development of hypertension, proteinuria, or evidence of glomerular bleeding 2, 3

Special Considerations in Young Women

• Women <60 years cannot be classified as high-risk based on age alone according to the 2025 AUA/SUFU guidelines, reflecting significantly lower risk of urothelial malignancy compared to men. 1
• However, gross hematuria overrides age-based risk stratification and requires full evaluation. 1, 2, 3
• Women with bladder cancer tend to present with more advanced disease and have higher case-fatality rates, emphasizing the importance of not delaying diagnosis. 3
• Exclude pregnancy before proceeding with CT urography; use MR urography or ultrasound with retrograde pyelography if pregnant. 2, 3